Navigation Links
U.S. FDA Accepts Aridol(TM) New Drug Application for Review
Date:5/13/2009

ecurities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson
     Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

     United States:
     Brandon Lewis
     Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
2. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
3. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
6. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
7. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
8. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
9. FDA Accepts Immucors Response to Warning Letter
10. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
11. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... This week Jonathan Watson will become the first student to ... engineering dual degree program . , ,Watson, a native of ... UW-Eau Claire and his bachelors degree in engineering from the ... great advantage in preparing for engineering course work because I ...
... and PowerPoint slides online is not enough, faculty and staff ... audio to liven up their course Web pages thanks to ... grant. , ,The services web site, Streaming Media at ... the production of streaming video and audio, comparisons of different ...
... has a new home: Health Sciences Learning Center ... health sciences on the UW-Madison campus. , ,Part of this ... DeLuca , associate dean for research and graduate studies at ... nursing, pharmacy and physical therapy students in one facility. DeLuca ...
Cached Biology Technology:Student to graduate in the Dual Degree Physics and Engineering Program 2University of Wisconsin enriches course web sites with streaming media 2UW Medical School to build Health Sciences Learning Center 2
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/17/2014)... in German . ... drugs. When treating overdoses, doctors are often limited to supportive ... there is a combination of drugs involved. So what can ... his grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute ... answer to this question. "The task was to develop an ...
(Date:10/16/2014)... of Marine Science have received a 3-year, $392,773 ... the streams and wetlands most vulnerable to sea-level ... governments and citizens conserve these important ecosystems. , ... tidal-marsh observations first gathered by VIMS scientists in ... today,s researchers accurately map the slow but inexorable ...
Breaking Biology News(10 mins):Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... one of the less common types of skin cancer but it ... percent). The five-year survival rate for early stage melanoma is ... cancer is detected late or there is recurrence. So a ... the goal is to remove as little tissue as possible while ...
... University of Maryland, in partnership with the University of ... received a $7.9 million federal grant to acquire a ... will help researchers unravel the mysteries of molecules and ... diseases. The grant is among the largest of ...
... Instructor in Medicine, University of Washington, and Associate, Human ... been chosen by the American Society for Microbiology (ASM) ... her outstanding work elucidating the role of neutralizing antibodies ... Health Division, this award recognizes an early career scientist ...
Cached Biology News:Seeing melanoma 2Seeing melanoma 3University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 3
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: